Ezetimibe (Zetia) vs Amlodipine: Real-World Evidence for Women

Why Comparing These Two Drugs Matters for Women

These drugs address different cardiovascular risk factors, but both become highly relevant to women in their 40s and beyond. Cardiovascular disease is the leading cause of death in women in the United States, accounting for 1 in 5 female deaths. The risk trajectory changes sharply around menopause: estrogen withdrawal raises LDL cholesterol, lowers HDL, increases arterial stiffness, and elevates blood pressure, meaning many women find themselves needing one or both of these medications within a few years of their final period.

The Core Difference

Ezetimibe reduces the cholesterol your gut absorbs. Amlodipine relaxes the smooth muscle in your arterial walls. One lowers a lab value; the other lowers a pressure reading. They do not substitute for each other.

The question "should I switch from Zetia to Amlodipine?" almost always signals a miscommunication somewhere in the treatment pathway. If a clinician is suggesting that switch, they are almost certainly addressing a new clinical problem, not replacing one drug with an equivalent. Understanding what each drug actually does helps you ask better questions at your appointment.

What Women's Cardiovascular Risk Looks Like Across Life Stages

During reproductive years, endogenous estrogen is broadly cardioprotective. The Framingham Heart Study data showed women develop coronary heart disease approximately 10 years later than men on average. That gap closes fast after menopause. By age 70, women's cardiovascular risk approaches men's, but women present with atypical symptoms more often and are less likely to receive guideline-recommended therapy at the same intensity as men. Both ezetimibe and amlodipine have been studied in mixed-sex populations where women were often underrepresented, a gap worth naming explicitly.

How Ezetimibe (Zetia) Works and What the Evidence Shows

Ezetimibe works by binding to the NPC1L1 transporter in your small intestine, blocking the absorption of both dietary and biliary cholesterol. Less cholesterol absorbed means less delivered to the liver, which in turn upregulates LDL receptors and pulls more LDL out of the bloodstream.

As monotherapy, ezetimibe lowers LDL by roughly 18 to 20%. That number rises substantially when it is combined with a statin: the IMPROVE-IT trial published in the New England Journal of Medicine in 2015 randomized 18,144 patients with acute coronary syndrome to simvastatin plus ezetimibe versus simvastatin plus placebo. After a median follow-up of 6 years, the ezetimibe group achieved a mean LDL of 53.7 mg/dL versus 69.5 mg/dL in the placebo group, translating to a 6.4% relative risk reduction in major adverse cardiovascular events (MACE).

Women in IMPROVE-IT

Women made up only 24% of the IMPROVE-IT population. A sex-stratified analysis showed the cardiovascular benefit was directionally consistent in women, though the subgroup was not powered to detect statistically significant differences independently. This is the kind of evidence gap clinicians should acknowledge rather than paper over. The benefit of lowering LDL is supported by decades of mechanistic and epidemiological data across sexes, but direct large-scale female-specific trial data remains thin.

Ezetimibe Across Female Life Stages

Reproductive years. Women with familial hypercholesterolaemia (FH) or severely elevated LDL during reproductive years need cholesterol management, but options are limited by safety concerns (see pregnancy section below). Ezetimibe is sometimes used in statin-intolerant women of reproductive age with documented very high LDL.

Perimenopause. The transition typically raises LDL by 10 to 14 mg/dL on average as estrogen levels fall. Women who were borderline candidates for cholesterol therapy before menopause often cross the treatment threshold during perimenopause. Ezetimibe is particularly useful as an add-on when statins alone are insufficient or poorly tolerated.

Post-menopause. This is when ezetimibe is most commonly initiated in women. Post-menopausal women with established atherosclerotic cardiovascular disease (ASCVD) or high 10-year risk (typically calculated using the Pooled Cohort Equations) who cannot achieve adequate LDL reduction on maximally tolerated statin therapy are good candidates.

Side Effects in Women

Ezetimibe's tolerability profile is generally favorable. The most common adverse effects are musculoskeletal pain (myalgia), diarrhea, and upper respiratory tract symptoms. Myalgia rates with ezetimibe monotherapy are substantially lower than with statins, making it attractive for statin-intolerant patients. Liver enzyme elevation is rare but worth monitoring. No sex-specific pharmacokinetic differences in ezetimibe have been published that would require dose adjustment, though women in early trials were underrepresented, so subtle differences may simply not have been detected.

How Amlodipine Works and What the Evidence Shows

Amlodipine is a long-acting dihydropyridine calcium channel blocker. It blocks L-type calcium channels in vascular smooth muscle, causing vasodilation. The result is lower peripheral vascular resistance, reduced blood pressure, and, in the setting of angina, reduced myocardial oxygen demand.

Its half-life of 30 to 50 hours means once-daily dosing provides stable 24-hour coverage, which matters because blood pressure surges in the early morning hours are associated with increased stroke and MI risk. Amlodipine is approved at 2.5 to 10 mg once daily for hypertension and chronic stable angina.

ASCOT-BPLA and What It Means for Women

The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA), published in the Lancet in 2005, randomized 19,257 patients with hypertension and at least three cardiovascular risk factors to amlodipine-based therapy (adding perindopril as needed) versus atenolol-based therapy (adding bendroflumethiazide as needed). The amlodipine arm showed a 23% reduction in non-fatal MI and fatal coronary heart disease compared to the atenolol arm, along with a 23% reduction in stroke. The trial was stopped early because of the superiority of the amlodipine arm.

Women comprised approximately 19% of ASCOT-BPLA. Sex-stratified results were not the primary endpoint, and the female subgroup was underpowered. The overall signal, however, established amlodipine-based regimens as first-line for hypertension in high-risk patients.

Amlodipine Across Female Life Stages

Reproductive years. Hypertension in younger women is less common than in men but not rare. Women with PCOS have elevated rates of hypertension and early metabolic dysfunction. A 2020 analysis in the Journal of Clinical Endocrinology & Metabolism noted that women with PCOS had a significantly higher prevalence of hypertension compared to age-matched controls, and amlodipine is a common second-line antihypertensive in this group when lifestyle modification and first-line agents are insufficient.

Perimenopause. Blood pressure rises in many women during the menopausal transition, independent of aging, likely due to estrogen withdrawal reducing nitric oxide-mediated vasodilation. A calcium channel blocker like amlodipine is often added during this window, particularly in women who are not candidates for hormone therapy or who have residual hypertension despite it.

Post-menopause. Hypertension affects more than 70% of women over age 65 in the United States. Amlodipine is a guideline-supported first-line agent in this population, endorsed by the 2017 ACC/AHA Hypertension Guidelines as one of four preferred drug classes for most patients.

Sex-Specific Side Effects of Amlodipine

Peripheral edema is amlodipine's most clinically significant side effect, and it occurs more frequently in women than in men. In clinical trials, edema rates in women receiving 10 mg/day reached 14.6% versus 5.6% in men. This disparity likely reflects differences in venous capacitance and hormonal influences on fluid retention. Clinicians sometimes reduce the dose, add an ACE inhibitor (which partially counteracts the edema), or switch to an alternative agent in women who develop significant lower extremity swelling.

Flushing and headache are also more commonly reported by women, particularly in perimenopause where they may be difficult to distinguish from vasomotor symptoms. This clinical overlap can complicate management: a woman reporting new flushing on amlodipine during the menopause transition may be experiencing a drug side effect, a hot flash, or both simultaneously.

Head-to-Head: A Direct Comparison Table

| Feature | Ezetimibe (Zetia) | Amlodipine | |---|---|---| | Drug class | Cholesterol absorption inhibitor | Calcium channel blocker (CCB) | | FDA-approved use | Hypercholesterolemia, sitosterolemia, mixed hyperlipidemia | Hypertension, stable angina, vasospastic angina | | Primary lab target | LDL cholesterol | Blood pressure | | Average effect size | LDL down 18-20% (mono); up to 25% added to statin | Systolic BP down 8-10 mmHg | | Dosing | 10 mg once daily (one dose) | 2.5-10 mg once daily | | Main side effect in women | Myalgia, diarrhea | Peripheral edema (higher rate in women), flushing | | Pregnancy | Contraindicated | Avoid first trimester; limited data in later pregnancy | | Perimenopause specific concern | LDL rise with estrogen loss | BP rise and flushing overlap with hot flashes | | Interchangeable? | No | No |

Pregnancy, Lactation, and Contraception

This is a required section for any drug comparison, and both drugs carry significant pregnancy-safety considerations.

Ezetimibe in Pregnancy and Lactation

Ezetimibe is contraindicated in pregnancy. Cholesterol is essential for fetal membrane synthesis, steroidogenesis, and neurological development. Disrupting cholesterol absorption during organogenesis carries a theoretical teratogenic risk, and animal studies at doses producing exposures greater than clinical human doses showed skeletal muscle and developmental toxicity. The FDA label states that ezetimibe should be discontinued as soon as pregnancy is recognized. There is no established safe window.

Because ezetimibe is almost always used alongside a statin (which is also contraindicated in pregnancy), women of reproductive age on this combination require reliable contraception. If pregnancy is desired, both drugs should be stopped before attempting conception, ideally with a washout period discussed with your clinician.

Lactation data is essentially absent for ezetimibe in humans. Animal studies show ezetimibe is excreted in breast milk. Given the theoretical risk and the absence of safety data, ezetimibe is not recommended during breastfeeding.

Amlodipine in Pregnancy and Lactation

Amlodipine is not a first-line antihypertensive in pregnancy. Preferred agents for gestational hypertension and chronic hypertension in pregnancy include labetalol, nifedipine (extended-release), and methyldopa, per ACOG Practice Bulletin No. 203. Amlodipine carries limited human data; what exists has not identified a clear teratogenic signal, but the evidence base is not large enough to classify it as safe.

Women who become pregnant while on amlodipine for chronic hypertension should discuss transition to a pregnancy-preferred agent with their clinician promptly. Amlodipine is excreted in breast milk at low levels. The WHO Model Formulary notes amlodipine as generally compatible with breastfeeding in the context of maternal benefit, but individual clinical judgment is required.

Who Is Each Drug Right For? A Life-Stage Framework

The following framework is designed by the WomanRx editorial team to help women and their clinicians think through which drug belongs in which clinical picture. This is not a substitute for individualized assessment.

Ezetimibe is most appropriate when you:

• Have elevated LDL and established ASCVD, or a 10-year ASCVD risk above 7.5% by the Pooled Cohort Equations
• Cannot tolerate statin doses high enough to reach your LDL goal
• Are post-menopausal and have seen your LDL climb since menopause
• Have familial hypercholesterolaemia and require add-on therapy to statin
• Are statin-intolerant and need an alternative cholesterol-lowering approach

Ezetimibe is not appropriate if you are pregnant, trying to conceive, or breastfeeding. It does not treat hypertension.

Amlodipine is most appropriate when you:

• Have confirmed hypertension (systolic BP consistently at or above 130 mmHg by 2017 ACC/AHA criteria)
• Have stable angina or vasospastic angina
• Are in perimenopause or post-menopause with new-onset hypertension
• Have PCOS with hypertension not controlled by lifestyle changes and first-line agents
• Need a once-daily, renally-safe antihypertensive (amlodipine does not require dose adjustment for renal impairment)

Amlodipine is not appropriate as your primary cholesterol therapy. It does not meaningfully lower LDL. It is not a first-choice agent in pregnancy.

Switching from Zetia to Amlodipine: When Does It Make Sense?

Rarely, and only if the clinical indication has changed.

A switch from ezetimibe to amlodipine is almost never a like-for-like substitution. The scenario where it might arise: a woman was on ezetimibe for LDL management, her cholesterol is now well-controlled (perhaps with statin dose adjustment or lifestyle change), and she has developed new hypertension requiring treatment. Her clinician adds or switches to amlodipine to address the blood pressure problem.

What a switch is not: trading one cardiovascular drug for another because they are "both heart medications." A clinician who suggests this without addressing LDL separately should be asked directly whether LDL management is being deprioritized and why.

If you have been told to switch and you are uncertain about the reasoning, asking these three questions is a reasonable starting point: What will now manage my LDL? Has my 10-year ASCVD risk been recalculated? What is my target blood pressure?

Real-World Evidence Beyond Clinical Trials

Large administrative database analyses have examined both drugs in real-world populations, though women-specific subgroup analyses remain sparse.

A 2021 cohort study using the UK Clinical Practice Research Datalink examined cardiovascular outcomes in patients initiated on various antihypertensives and found amlodipine associated with lower rates of hospitalization for cardiovascular events compared to several comparators in routine clinical practice, consistent with trial data. The cohort was roughly 50% female.

For ezetimibe, a 2019 real-world analysis published in the American Heart Journal found that adherence to ezetimibe in clinical practice was substantially lower than in trials, approximately 50 to 60% at one year versus over 90% in IMPROVE-IT. Women were not analyzed separately, but real-world adherence data matters because a drug's trial-proven benefit only materializes if the patient actually takes it consistently.

Amlodipine's adherence in real-world settings is generally high, attributed to its once-daily dosing, low cost (generic amlodipine is widely available for under $10/month), and tolerability except for the edema issue discussed above.

Drug Interactions and Concurrent Medications Relevant to Women

Both drugs have interaction profiles that matter in the context of medications commonly used by women.

Ezetimibe interactions: Cholestyramine and other bile acid sequestrants reduce ezetimibe absorption; these should be separated by at least four hours. Cyclosporine increases ezetimibe exposure substantially. Ezetimibe does not meaningfully inhibit or induce CYP450 enzymes, which simplifies its interaction profile compared to statins.

Amlodipine interactions: Amlodipine is metabolized by CYP3A4. Strong CYP3A4 inhibitors, including some antifungals (fluconazole, itraconazole) commonly used in women for recurrent vaginal candidiasis, can increase amlodipine exposure and amplify its hypotensive and edema-producing effects. Grapefruit juice is a mild inhibitor worth mentioning. Simvastatin at doses above 20 mg should not be combined with amlodipine due to increased simvastatin exposure and myopathy risk, per the FDA Drug Safety Communication.

Women on hormone therapy (HT) for menopausal symptoms should be aware that estrogen-containing therapy can mildly increase blood pressure in some patients, potentially affecting amlodipine dosing requirements. Progesterone-only therapy generally has a neutral to slightly favorable effect on blood pressure.

Monitoring: What to Track on Each Drug

On ezetimibe: Fasting lipid panel at 6 to 12 weeks after initiation, then annually once stable. Liver function tests if symptomatic. No routine CK monitoring is required for ezetimibe monotherapy (unlike statins).

On amlodipine: Blood pressure measurement at each clinical visit, ideally with home monitoring to capture the full 24-hour profile. Assess for peripheral edema at each visit. No routine lab monitoring is required, though basic metabolic panel is reasonable in patients with renal disease.

Both drugs are available as generics and are generally covered by most insurance plans and pharmacy benefit programs, though formulary placement varies.